报道

订阅

MedSci主页 / 所有栏目 / 报道

2018年全球药物销售额TOP100：排行榜

2019-02-22 佚名 新康界

药物销售额OpdivoKeytruda
关注

排名第一的Humria在仿制药的冲击下，虽然没有突破200亿美元大关，但是仍超过第二名100亿美元以上

排名第一的Humria在仿制药的冲击下，虽然没有突破200亿美元大关，但是仍超过第二名100亿美元以上。

Keytruda反超Opdivo，位列第4位，较2017年上升18位；销售额从2017年的38.09亿美元增长到2018年的71.71亿美元，增速达到88.26％。

需要注意的是，TOP100排行榜中第4到第9位之间的差距非常小，其中聚集了全球最畅销的5种抗癌药物：PD-1单抗双雄Keytruda和Opdivo、罗氏的三巨头，呈现出新老交替的趋势。

与去年相比，TOP10的门槛提高了接近10亿美元，从约56亿美元提高到65亿美元，TOP100的门槛提高了接近1亿美元，从约12亿美元提高到约13亿美元。（详情回顾请点击《2017年全球药物销售额TOP100 | 排行榜》）



数据来源：各公司报表

注：红色字体为预测值

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687329, encodeId=b4e7168e32992, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Jan 13 13:56:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649852, encodeId=849a164985258, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Mon Apr 29 15:56:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086032, encodeId=8f0f20860327f, content=<a href='/topic/show?id=11278e89978' target=_blank style='color:#2F92EE;'>#药物销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87899, encryptionId=11278e89978, topicName=药物销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 13 21:56:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379916, encodeId=77ac13e991649, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495582, encodeId=b1eb14955827b, content=<a href='/topic/show?id=92745665668' target=_blank style='color:#2F92EE;'>#排行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56656, encryptionId=92745665668, topicName=排行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb39173897, createdName=wujh_7312822, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2020-01-13 1249862am81(暂无昵称)

    #销售#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1687329, encodeId=b4e7168e32992, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Jan 13 13:56:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649852, encodeId=849a164985258, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Mon Apr 29 15:56:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086032, encodeId=8f0f20860327f, content=<a href='/topic/show?id=11278e89978' target=_blank style='color:#2F92EE;'>#药物销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87899, encryptionId=11278e89978, topicName=药物销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 13 21:56:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379916, encodeId=77ac13e991649, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495582, encodeId=b1eb14955827b, content=<a href='/topic/show?id=92745665668' target=_blank style='color:#2F92EE;'>#排行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56656, encryptionId=92745665668, topicName=排行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb39173897, createdName=wujh_7312822, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2019-04-29 respect

    #TOP10#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1687329, encodeId=b4e7168e32992, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Jan 13 13:56:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649852, encodeId=849a164985258, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Mon Apr 29 15:56:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086032, encodeId=8f0f20860327f, content=<a href='/topic/show?id=11278e89978' target=_blank style='color:#2F92EE;'>#药物销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87899, encryptionId=11278e89978, topicName=药物销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 13 21:56:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379916, encodeId=77ac13e991649, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495582, encodeId=b1eb14955827b, content=<a href='/topic/show?id=92745665668' target=_blank style='color:#2F92EE;'>#排行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56656, encryptionId=92745665668, topicName=排行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb39173897, createdName=wujh_7312822, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2019-07-13 chendoc242

    #药物销售额#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1687329, encodeId=b4e7168e32992, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Jan 13 13:56:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649852, encodeId=849a164985258, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Mon Apr 29 15:56:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086032, encodeId=8f0f20860327f, content=<a href='/topic/show?id=11278e89978' target=_blank style='color:#2F92EE;'>#药物销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87899, encryptionId=11278e89978, topicName=药物销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 13 21:56:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379916, encodeId=77ac13e991649, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495582, encodeId=b1eb14955827b, content=<a href='/topic/show?id=92745665668' target=_blank style='color:#2F92EE;'>#排行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56656, encryptionId=92745665668, topicName=排行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb39173897, createdName=wujh_7312822, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2019-02-24 zxl729

    #销售额#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1687329, encodeId=b4e7168e32992, content=<a href='/topic/show?id=df72966659b' target=_blank style='color:#2F92EE;'>#销售#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96665, encryptionId=df72966659b, topicName=销售)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bca28361924, createdName=1249862am81(暂无昵称), createdTime=Mon Jan 13 13:56:00 CST 2020, time=2020-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649852, encodeId=849a164985258, content=<a href='/topic/show?id=f1e41e642cd' target=_blank style='color:#2F92EE;'>#TOP10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17642, encryptionId=f1e41e642cd, topicName=TOP10)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb7b23929551, createdName=respect, createdTime=Mon Apr 29 15:56:00 CST 2019, time=2019-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086032, encodeId=8f0f20860327f, content=<a href='/topic/show?id=11278e89978' target=_blank style='color:#2F92EE;'>#药物销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87899, encryptionId=11278e89978, topicName=药物销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8994206, createdName=chendoc242, createdTime=Sat Jul 13 21:56:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379916, encodeId=77ac13e991649, content=<a href='/topic/show?id=979f966e5f7' target=_blank style='color:#2F92EE;'>#销售额#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96675, encryptionId=979f966e5f7, topicName=销售额)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495582, encodeId=b1eb14955827b, content=<a href='/topic/show?id=92745665668' target=_blank style='color:#2F92EE;'>#排行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56656, encryptionId=92745665668, topicName=排行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2cb39173897, createdName=wujh_7312822, createdTime=Sun Feb 24 12:56:00 CST 2019, time=2019-02-24, status=1, ipAttribution=)]
    2019-02-24 wujh_7312822

    #排行#

    0